Heart failure

Windtree Therapeutics Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (SEISMiC) Published in the European Journal of Heart Failure

Retrieved on: 
Wednesday, September 28, 2022

WARRINGTON, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today reported that the results of its positive Phase 2 istaroxime study in early cardiogenic shock were published in the European Journal of Heart Failure ( https://doi.org/10.1002/ejhf.2629 ).

Key Points: 
  • WARRINGTON, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today reported that the results of its positive Phase 2 istaroxime study in early cardiogenic shock were published in the European Journal of Heart Failure ( https://doi.org/10.1002/ejhf.2629 ).
  • Windtree conducted a study called SEISMiC of istaroxime in patients experiencing early cardiogenic shock due to heart failure.
  • The positive results of the SEISMiC study are consistent with previous Phase 2 studies in acute heart failure and help substantiate and advance the rationale for istaroxime as a potential treatment for cardiogenic shock.
  • This study represents a potentially important innovative advancement in the treatment for heart failure related cardiogenic shock patients in the future, said Craig Fraser, President and Chief Executive Officer of Windtree.

CLIMATE CHANGE AND HEALTH INEQUITY A DEADLY MIX FOR THE MOST VULNERABLE: WORLD HEART FEDERATION

Retrieved on: 
Wednesday, September 28, 2022

World leaders must step up efforts on the two biggest threats of our time: climate change and global health inequity."

Key Points: 
  • World leaders must step up efforts on the two biggest threats of our time: climate change and global health inequity."
  • Everyone is encouraged to get involved in World Heart Day and to learn more about better heart health.
  • This World Heart Day, they are proud to continue to support the World Heart Federation.
  • [2]In 2022, the World Heart Federation conducted a global pulse survey of 2500 people across 25 countries.

CLIMATE CHANGE AND HEALTH INEQUITY A DEADLY MIX FOR THE MOST VULNERABLE: WORLD HEART FEDERATION

Retrieved on: 
Wednesday, September 28, 2022

World leaders must step up efforts on the two biggest threats of our time: climate change and global health inequity."

Key Points: 
  • World leaders must step up efforts on the two biggest threats of our time: climate change and global health inequity."
  • Everyone is encouraged to get involved in World Heart Day and to learn more about better heart health.
  • This World Heart Day, they are proud to continue to support the World Heart Federation.
  • [2]In 2022, the World Heart Federation conducted a global pulse survey of 2500 people across 25 countries.

BioAlberta Recognizes Alberta Innovators and Entrepreneurs at Annual Health and Life Sciences Showcase & Awards Ceremony

Retrieved on: 
Wednesday, September 28, 2022

The awards were presented at BioAlbertas Annual Health and Life Sciences Showcase & Awards Ceremony, held in Calgary on September 27th.

Key Points: 
  • The awards were presented at BioAlbertas Annual Health and Life Sciences Showcase & Awards Ceremony, held in Calgary on September 27th.
  • This award acknowledges a company that has shown significant achievement within the marketplace and Albertas business community through strong performance or a leadership role.
  • Accepting this award Co-Founders Matt Anderson-Baron and Jalene Anderson-Baron said: We are very honored to be recognized as the BioAlberta company of the year.
  • BioAlberta is the voice and champion for life sciences in Alberta, committed to creating a thriving and competitive industry by facilitating and accelerating economic diversification, investment attraction and job growth.

Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America

Retrieved on: 
Wednesday, September 28, 2022

The poster will be presented for general viewing within the "Basic and Translational Science" category of the HFSA2022 Scientific Programme on September 30, 2022, from 6:15 6:30 PM EDT.

Key Points: 
  • The poster will be presented for general viewing within the "Basic and Translational Science" category of the HFSA2022 Scientific Programme on September 30, 2022, from 6:15 6:30 PM EDT.
  • The Heart Failure Society of America is a multidisciplinary organization working to improve and expand heart failure care through collaboration, education, research, innovation, and advocacy.
  • The Company's lead product candidate, CardiolRx, is an oral pharmaceutical that is being clinically developed for use in CVD.
  • In addition, CardiolRx is being evaluated in a Phase II/III multi-national, randomized, double-blind, placebo-controlled study (the "LANCER" trial).

Implicity Continues Rapid Growth and Expansion with Hiring of Two New Senior Leaders

Retrieved on: 
Wednesday, September 28, 2022

CAMBRIDGE, Mass., Sept. 28, 2022 /PRNewswire/ -- Implicity®, a leader in remote patient monitoring and cardiac data management solutions, announced its continued growth with the appointment of two new senior-level executives. Vanessa Joyce was named the Company's new Vice President of Sales for North America, and Megan Grosz was appointed Global Head of Marketing and Communications.

Key Points: 
  • Both Vanessa and Megan bring a wealth of industry knowledge to support our rapid global expansion, particularly in the U.S.where we see a dramatic rise in remote patient monitoring," said Dr. Arnaud Rosier, Electrophysiologist, CEO, and Co-founder of Implicity.
  • Vanessa Joyce comes to Implicity with more than 30 years of experience in MedTech marketing and clinical aspects ofthe Cardiac, Heart Failure, and Electrophysiology industries.
  • "I'm excited to apply my expertise and experience to establish Implicity as the primary CIED remote monitoring software solution," said Joyce.
  • Implicity proudly protects more than 70,000 patients in more than 100 medical facilities across the United States and Europe.

Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program

Retrieved on: 
Wednesday, September 28, 2022

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the fifth annual Cytokinetics Communications Grant Program. The program awards five grants worth $20,000 each to patient advocacy organizations serving the amyotrophic lateral sclerosis (ALS), heart failure or hypertrophic cardiomyopathy (HCM) communities, and is intended to support increased capacity in communications and outreach.

Key Points: 
  • Deadline for Applications is November 11th, 2022
    SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the fifth annual Cytokinetics Communications Grant Program.
  • The Cytokinetics Communications Grant Program supports patient advocacy organizations in expanding their reach, awareness and community engagement by providing resources for new or crucial communication or outreach initiatives that would otherwise be challenging to implement.
  • Funding from the Cytokinetics Communications Grant program supports programming or personnel, depending on each organizations needs.
  • Organizations applying for the grant are required to submit a proposal outlining what activities the Cytokinetics Communications Grant Program will support and the potential impact of the funding.

HMA conference to look at future of Hospital at Home model in Asia

Retrieved on: 
Wednesday, September 28, 2022

This is why Hospital Management Asia is organising the [email protected] Asia conference, with Singapore's MOH Office for Healthcare Transformation as knowledge partner.

Key Points: 
  • This is why Hospital Management Asia is organising the [email protected] Asia conference, with Singapore's MOH Office for Healthcare Transformation as knowledge partner.
  • The one-day event on 25 November will delve into different aspects of hospital at home programmes with a particular focus on Singapore's [email protected] (Mobile Inpatient Care at Home).
  • Prof Dan and Dr Montalto will be joining the first panel discussion looking at whether Hospital at Home is the future of acute medicine.
  • Registration is now open - click on this link for more information on the agenda, speakers, and to register: www.hospitalmanagementasia.com/events/hospital-at-home/.

HEALTH EQUITY ADVOCATES LAUNCH CAMPAIGN IN MASSACHUSETTS TO ELIMINATE RACISM IN PATIENT CARE WITH AN INNOVATIVE, RACE-CONSCIOUS APPROACH

Retrieved on: 
Tuesday, September 27, 2022

BOSTON, Sept. 27, 2022 /PRNewswire/ -- A prominent group of health professionals, community leaders, and healthcare equity advocates today launched a campaign to raise awareness of successful race-conscious approaches to healthcare delivery in Massachusetts that target institutional racism and can bring transformational change to health care systems.

Key Points: 
  • The campaign educates hospital administrators, lawmakers, social justice advocates and communities about the value of race-conscious interventions, such as those implemented under the Healing ARC framework.
  • The Healing ARC is a collaborative approach that helps rectify patient care inequities, while counteringthe notion that race-blind solutions alone effectively fix systems broken by racism.
  • In response, physicians developed a race-conscious, Healing ARC care modelto address the racial inequities and enhance accountability.
  • "The approach addresses two antiracism goals byproviding clinician education through acknowledgment of a racial inequity and providing a path of redress for patients of color."

Updated diabetes guideline released by the American Association of Clinical Endocrinology features the latest state-of-the-science in diabetes care

Retrieved on: 
Tuesday, September 27, 2022

JACKSONVILLE, Fla., Sept. 27, 2022 /PRNewswire/ -- The American Association of Clinical Endocrinology (AACE) is proud to announce the release of its updated guideline for the care and management of people with or at risk for diabetes mellitus.

Key Points: 
  • JACKSONVILLE, Fla., Sept. 27, 2022 /PRNewswire/ -- The American Association of Clinical Endocrinology (AACE) is proud to announce the release of its updated guideline for the care and management of people with or at risk for diabetes mellitus.
  • The guideline features 170 updated and new evidence-based clinical practice recommendations for diabetes at every stage, including prevention, diagnosis, and treatment.
  • "The guideline is framed to support person-centered, team-based clinical decision-making, which importantly puts the patient at the center to improve care for people with prediabetes and diabetes."
  • The 2022 guideline update synthesizes thousands of articles to provide health care professionals with the latest evidence-based information on the total care of diabetes.